Form 4: Ionis Pharmaceuticals Executive Richard S. Geary Acquires 22,000 Stock Options

EVP and Chief Development Officer of Ionis Pharmaceuticals, Richard S. Geary, reports the acquisition of 22,000 stock options.

Summary

• Richard S. Geary, EVP and Chief Development Officer of Ionis Pharmaceuticals, acquired 22,000 non-qualified stock options on January 2, 2025.
• The options have an exercise price of $34.69.
• The options were granted under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.
• The grant date was January 2, 2025, and the expiration date is January 1, 2035.
• 25% of the shares subject to the option will vest and become exercisable on January 2, 2026.
• The remaining shares will vest in 36 equal monthly installments over the next 3 years.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard executive compensation disclosure. The grant of options can be seen as a positive sign of alignment, but it's not overwhelmingly positive.

Positives

• The acquisition of stock options by a high-ranking executive could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain explicit forward-looking statements about the company's overall future outlook, but the vesting schedule of the options suggests a multi-year commitment from the executive.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Executive compensation packages, including stock options, are common in the pharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their executive compensation plans.
• The vesting schedule and exercise price are typical components of such agreements, designed to incentivize long-term performance.

Stakeholder Impact

• The granting of stock options can incentivize management to improve company performance, potentially benefiting shareholders.
• Employees may view executive compensation packages as a reflection of the company's overall health and commitment to its workforce.

Key Dates